EA033604B1 - Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид - Google Patents

Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид Download PDF

Info

Publication number
EA033604B1
EA033604B1 EA201691541A EA201691541A EA033604B1 EA 033604 B1 EA033604 B1 EA 033604B1 EA 201691541 A EA201691541 A EA 201691541A EA 201691541 A EA201691541 A EA 201691541A EA 033604 B1 EA033604 B1 EA 033604B1
Authority
EA
Eurasian Patent Office
Prior art keywords
seq
baff
antibody
variable domain
sequences
Prior art date
Application number
EA201691541A
Other languages
English (en)
Russian (ru)
Other versions
EA201691541A1 (ru
Inventor
Scott Ronald Brodeur
Keith Canada
Pankaj Gupta
Amy Marie Nicoletti
Qi Pan
Sanjaya Singh
Michael Dziegelewski
Philip Nicholas Gorman
Ashraf Khalil
John MIGLIETTA
David Presky
Tao Wu
Haiguang Xiao
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of EA201691541A1 publication Critical patent/EA201691541A1/ru
Publication of EA033604B1 publication Critical patent/EA033604B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA201691541A 2014-01-31 2015-01-30 Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид EA033604B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461934124P 2014-01-31 2014-01-31
PCT/US2015/013711 WO2016039801A1 (en) 2014-01-31 2015-01-30 Novel anti-baff antibodies

Publications (2)

Publication Number Publication Date
EA201691541A1 EA201691541A1 (ru) 2016-12-30
EA033604B1 true EA033604B1 (ru) 2019-11-08

Family

ID=53754266

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691541A EA033604B1 (ru) 2014-01-31 2015-01-30 Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид

Country Status (14)

Country Link
US (3) US9840543B2 (enExample)
EP (1) EP3099715B1 (enExample)
JP (1) JP6511459B2 (enExample)
KR (1) KR20160113715A (enExample)
CN (1) CN105873949B (enExample)
AU (1) AU2015315834B2 (enExample)
BR (1) BR112016014731A2 (enExample)
CA (1) CA2934965A1 (enExample)
CL (1) CL2016001742A1 (enExample)
EA (1) EA033604B1 (enExample)
IL (2) IL246113B (enExample)
MX (1) MX367661B (enExample)
PH (1) PH12016501366A1 (enExample)
WO (1) WO2016039801A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
CA2934965A1 (en) 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Novel anti-baff antibodies
BR112018001255A2 (pt) * 2015-07-23 2018-09-11 Boehringer Ingelheim International Gmbh composto direcionado à il-23a e fator de ativação de células b (baff) e seus usos
WO2017223534A2 (en) * 2016-06-24 2017-12-28 Anthera Pharmaceuticals, Inc. Methods of treating iga nephropathy and henoch-schönlein purpura nephritis using a b-cell activating factor (baff) inhibitor
WO2018006824A1 (zh) * 2016-07-06 2018-01-11 上海开拓者生物医药有限公司 一种BLyS抗体及其制备方法和应用
US10869522B2 (en) 2016-11-04 2020-12-22 Totes Isotoner Corporation Footwear, and methods of preparing same
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
EP3735272A4 (en) * 2018-01-05 2021-09-22 Biograph 55, Inc. COMPOSITIONS AND METHODS FOR IMMUNO CANCEROTHERAPY
CA3096222A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
WO2019210168A1 (en) * 2018-04-26 2019-10-31 University Of Virginia Patent Foundation Compositions and methods for treating abdominal aortic aneurysm
JP7701913B2 (ja) 2019-10-03 2025-07-02 エータイアー ファーマ， インコーポレイテッド 抗ｎｒｐ２抗体を含む組成物および方法
CA3169301A1 (en) * 2020-03-18 2021-09-23 Shyr Jiann Li Anti-il4 receptor antibodies for veterinary use
CN113637073B (zh) * 2020-05-11 2024-04-12 上海赛比曼生物科技有限公司 Bcma抗体及其制备和应用
IL302412A (en) 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
CN112516303A (zh) * 2020-11-18 2021-03-19 华中科技大学同济医学院附属协和医院 Baff抗体在制备脓毒血症药物中的应用
CN116178530A (zh) * 2021-09-26 2023-05-30 上海君实生物医药科技股份有限公司 抗体在治疗SARS-CoV-2感染的用途
CN118440195B (zh) * 2022-06-17 2025-04-08 东莞市朋志生物科技有限公司 抗脂联素抗体、检测脂联素的试剂和试剂盒
US12173081B2 (en) 2023-03-21 2024-12-24 Biograph 55, Inc. CD19/CD38 multispecific antibodies
WO2025125137A1 (en) * 2023-12-11 2025-06-19 Glaxosmithkline Intellectual Property Development Limited Baff specific antibodies
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070694A1 (en) * 2001-08-16 2005-03-31 Gelfanova Valentina Pavlovna Antagonistic anti-htnfsf13b human antibodies
US20150218267A1 (en) * 2014-01-31 2015-08-06 Boehringer Ingelheim International Gmbh Novel anti-baff antibodies

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH08500826A (ja) 1992-08-21 1996-01-30 ジェネンテク，インコーポレイテッド Ｌｆａ−１仲介疾患を処置する方法
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ES2204528T3 (es) 1999-01-25 2004-05-01 Biogen, Inc. Baff, sus inhibidores y su uso en la modulacion de la respuesta de las celulas b.
MXPA02012434A (es) 2000-06-16 2004-09-06 Cambridge Antibody Tech Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
JP5570681B2 (ja) 2004-08-31 2014-08-13 興和株式会社 抗ヒトｂａｆｆ抗体
US7846662B2 (en) 2004-09-15 2010-12-07 Kowa Company, Ltd. Method of screening Baff suppressor or inhibitor
US8853367B1 (en) 2004-09-15 2014-10-07 The Uab Research Foundation Compositions and methods for modulating rank activities
WO2007014390A2 (en) * 2005-07-28 2007-02-01 Biogen Idec Ma Inc. Methods of targeting baff
US8617545B2 (en) 2005-10-13 2013-12-31 Biogen Idec Ma Inc. Methods for use with BAFF antagonists
TW200833711A (en) 2006-12-22 2008-08-16 Genentech Inc Antibodies to insulin-like growth factor receptor
JP5767109B2 (ja) 2008-07-17 2015-08-19 ノバルティス アーゲー 治療抗体を用いる組成物及び方法
US20130028897A1 (en) * 2009-04-27 2013-01-31 Ali Naji Methods for reducing the level of alloantibodies in a subject
WO2011031835A1 (en) 2009-09-09 2011-03-17 The Uab Research Foundation Chimeric dr5 polypeptides and uses thereof
CA2777542A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
CA2789071C (en) * 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
PL2663575T3 (pl) 2011-10-28 2015-03-31 Regeneron Pharma Humanizowane IL-6 i receptor IL-6
AR090626A1 (es) 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070694A1 (en) * 2001-08-16 2005-03-31 Gelfanova Valentina Pavlovna Antagonistic anti-htnfsf13b human antibodies
US20150218267A1 (en) * 2014-01-31 2015-08-06 Boehringer Ingelheim International Gmbh Novel anti-baff antibodies

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HSU HAILING; KHARE SANJAY D; LEE FRANCES; MINER KENT; HU YI-LING; STOLINA MARINA; HAWKINS NESSA; CHEN QING; HO SHU-YIN JOANNE; MIN: "A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease.", CLINICAL AND EXPERIMENTAL RHEUMATOLOGY., PACINI, PISA, IT, vol. 30, no. 2, 1 January 2012 (2012-01-01), IT, pages 197 - 201, XP009186073, ISSN: 0392-856X *
KRISTINE KIKLY, JOSEPH MANETTA, HOLLY BINA, PAUL RYAN, NILES FOX, DERRICK R. WITCHER: "Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor", JOURNAL OF INFLAMMATION RESEARCH, DOVE MEDICAL PRESS, 1 August 2014 (2014-08-01), pages 121, XP055174727, ISSN: 11787031, DOI: 10.2147/JIR.S67751 *
MACKAY FABIENNE; SCHNEIDER PASCAL: "Cracking the BAFF code", NATURE REVIEWS IMMUNOLOGY, NATURE PUB. GROUP, GB, vol. 9, no. 7, 1 July 2009 (2009-07-01), GB, pages 491 - 502, XP009154275, ISSN: 1474-1733, DOI: 10.1038/nri2572 *
WILLIAM STOHL, MERRILL JOAN T., LOONEY R. JOHN, BUYON JILL, WALLACE DANIEL J., WEISMAN MICHAEL H., GINZLER ELLEN M., COOKE BLAIRE,: "Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials", ARTHRITIS RESEARCH & THERAPY, vol. 6, no. 1, 1 August 2015 (2015-08-01), pages 5537, XP055213755, DOI: 10.1186/s13075-015-0741-z *
ZHENG LIU; ANNE DAVIDSON;: "BAFF inhibition: A new class of drugs for the treatment of autoimmunity", EXPERIMENTAL CELL RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 317, no. 9, 9 February 2011 (2011-02-09), AMSTERDAM, NL, pages 1270 - 1277, XP028205665, ISSN: 0014-4827, DOI: 10.1016/j.yexcr.2011.02.005 *

Also Published As

Publication number Publication date
CA2934965A1 (en) 2016-03-17
US20180127474A1 (en) 2018-05-10
US20150218267A1 (en) 2015-08-06
MX367661B (es) 2019-08-30
BR112016014731A2 (pt) 2017-09-19
CN105873949A (zh) 2016-08-17
WO2016039801A1 (en) 2016-03-17
US9840543B2 (en) 2017-12-12
US10377804B2 (en) 2019-08-13
CL2016001742A1 (es) 2017-07-28
EA201691541A1 (ru) 2016-12-30
PH12016501366A1 (en) 2016-08-15
EP3099715B1 (en) 2020-11-18
IL266864A (en) 2019-07-31
CN105873949B (zh) 2024-09-27
KR20160113715A (ko) 2016-09-30
JP6511459B2 (ja) 2019-05-15
IL246113A0 (en) 2016-07-31
IL246113B (en) 2019-06-30
US20190309034A1 (en) 2019-10-10
EP3099715A1 (en) 2016-12-07
JP2017505622A (ja) 2017-02-23
US11370818B2 (en) 2022-06-28
AU2015315834B2 (en) 2019-12-12
MX2016009877A (es) 2016-10-14
AU2015315834A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
US11370818B2 (en) Anti-BAFF antibodies
US20250101093A1 (en) Anti-il-23 antibodies
TWI631957B (zh) 抗－ｉｌ－２３抗體
EA031948B1 (ru) Антитело к il-36r или его антигенсвязывающий фрагмент, выделенный полинуклеотид, клетка-хозяин и способ получения этого антитела или его фрагмента, содержащая их фармацевтическая композиция и применение антитела или его фрагмента и композиции
EA040834B1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К IL-23p19 ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, ЕГО ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ УКАЗАННОЕ АНТИТЕЛО
OA16388A (en) Anti-IL-23 antibodies.
EA042716B1 (ru) Фармацевтическая композиция, содержащая антитело к il-23р19, и ее применение

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU